These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29308279)

  • 1. The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet's disease.
    Adeeb F; Ng WL; Khan MU; Devlin J; Stack AG; Fraser AD
    Eur J Rheumatol; 2017 Dec; 4(4):254-259. PubMed ID: 29308279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.
    Zhan S; Liu C; Li N; Li T; Tian Z; Zhao M; Wu D; Chen M; Zeng Z; Zhuang X
    Therap Adv Gastroenterol; 2022; 15():17562848221116666. PubMed ID: 36082178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey.
    Bektaş M; Özer MD; Oğuz E
    Clin Immunol; 2024 Jul; 264():110239. PubMed ID: 38734038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
    Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
    BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future treatments for Behçet's uveitis: road to remission.
    Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
    Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
    Batu ED; Sener S; Cam V; Aktay Ayaz N; Ozen S
    BioDrugs; 2023 Nov; 37(6):813-828. PubMed ID: 37382804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
    Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
    Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching of anti-TNF-α agents in Behçet's disease.
    Furuta S; Chow YW; Chaudhry AN; Jayne D
    Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S62-8. PubMed ID: 23010387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of severe complications in Behçet's disease with TNF inhibitors.
    Desbois AC; Vallet H; Domont F; Comarmond C; Cacoub P; Saadoun D
    Expert Opin Biol Ther; 2017 Jul; 17(7):853-859. PubMed ID: 28503960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological therapy for ocular Behçet's disease with off-label drug prescription in Turkey.
    Citirik M; Ucgul Atilgan C; Rahmanlar H; Alkan A; Gursoz H
    Eur J Hosp Pharm; 2023 Jan; 30(1):53-56. PubMed ID: 34083220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
    Park Y; Cheon JH
    Curr Gastroenterol Rep; 2020 Mar; 22(5):24. PubMed ID: 32193746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behçet's Disease-related Budd-Chiari Syndrome Successfully Managed with anti-TNF Antibody: A Case Report and Review of the Literature.
    Erul E; Uzun GS; Koksal D; Keskin O; Uysal S; Inkaya AC; Kalyoncu U
    Eur J Case Rep Intern Med; 2022; 9(8):003515. PubMed ID: 36093305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
    Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of non-TNF biologics for the treatment of neuro-Behçet's disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab.
    Karabulut Y
    Eur J Rheumatol; 2021 Oct; 8(4):223-227. PubMed ID: 34554909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.